Proteoglycans as potential microenvironmental biomarkers for colon cancer

[1]  A. Khurana,et al.  The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics , 2014, Front. Oncol..

[2]  I. Ernberg,et al.  Transcriptional Activity of Heparan Sulfate Biosynthetic Machinery is Specifically Impaired in Benign Prostate Hyperplasia and Prostate Cancer , 2014, Front. Oncol..

[3]  R. Linhardt,et al.  Carbohydrate-containing molecules as potential biomarkers in colon cancer. , 2014, Omics : a journal of integrative biology.

[4]  A. Astudillo,et al.  Neuroendocrine Tumors Show Altered Expression of Chondroitin Sulfate, Glypican 1, Glypican 5, and Syndecan 2 Depending on Their Differentiation Grade , 2014, Front. Oncol..

[5]  C. Gialeli,et al.  Syndecans as Modulators and Potential Pharmacological Targets in Cancer Progression , 2014, Front. Oncol..

[6]  H. Lortat-Jacob,et al.  Post-Synthetic Regulation of HS Structure: The Yin and Yang of the Sulfs in Cancer , 2014, Front. Oncol..

[7]  K. Shimada,et al.  Syndecan‐1 (CD138) contributes to prostate cancer progression by stabilizing tumour‐initiating cells , 2013, The Journal of pathology.

[8]  Pavel Soucek,et al.  Differential expression and prognostic role of selected genes in colorectal cancer patients. , 2013, Anticancer research.

[9]  R. Ricci,et al.  Syndecan-2 is upregulated in colorectal cancer cells through interactions with extracellular matrix produced by stromal fibroblasts , 2013, BMC Cell Biology.

[10]  E. Oh,et al.  Targeting syndecans: a promising strategy for the treatment of cancer , 2013, Expert opinion on therapeutic targets.

[11]  A. V. Suhovskih,et al.  Proteoglycan Expression in Normal Human Prostate Tissue and Prostate Cancer , 2013, ISRN oncology.

[12]  Rosanna La Rocca,et al.  Human NK Cells Selective Targeting of Colon Cancer–Initiating Cells: A Role for Natural Cytotoxicity Receptors and MHC Class I Molecules , 2013, The Journal of Immunology.

[13]  So Hyun Kim,et al.  The extracellular domain of syndecan-2 regulates the interaction of HCT116 human colon carcinoma cells with fibronectin. , 2013, Biochemical and biophysical research communications.

[14]  D. Nowak,et al.  Overexpression of lumican affects the migration of human colon cancer cells through up-regulation of gelsolin and filamentous actin reorganization. , 2012, Experimental cell research.

[15]  A. Tsatsakis,et al.  Insights into targeting colon cancer cell fate at the level of proteoglycans / glycosaminoglycans. , 2012, Current medicinal chemistry.

[16]  Wancai Yang,et al.  Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. , 2012, Carcinogenesis.

[17]  Yuehua Gong,et al.  Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers , 2012, Clinical and Experimental Medicine.

[18]  E. Oh,et al.  Syndecan-2 cytoplasmic domain regulates colon cancer cell migration via interaction with syntenin-1. , 2011, Biochemical and biophysical research communications.

[19]  Renato V Iozzo,et al.  Proteoglycans in cancer biology, tumour microenvironment and angiogenesis , 2011, Journal of cellular and molecular medicine.

[20]  Shi Chen,et al.  Anti-tumor effects of proteoglycan from Phellinus linteus by immunomodulating and inhibiting Reg IV/EGFR/Akt signaling pathway in colorectal carcinoma. , 2011, International journal of biological macromolecules.

[21]  M. Mikuła,et al.  Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors , 2011, Functional & Integrative Genomics.

[22]  B. Klein,et al.  SULFs in human neoplasia: implication as progression and prognosis factors , 2011, Journal of Translational Medicine.

[23]  A. Theocharis,et al.  Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting , 2010, The FEBS journal.

[24]  I. Han,et al.  Syndecan-2 regulates cell migration in colon cancer cells through Tiam1-mediated Rac activation. , 2010, Biochemical and biophysical research communications.

[25]  J. Seong,et al.  Syndecan-2 Functions as a Docking Receptor for Pro-matrix Metalloproteinase-7 in Human Colon Cancer Cells* , 2009, The Journal of Biological Chemistry.

[26]  Jung Weon Lee,et al.  Syndecan-2 overexpression regulates adhesion and migration through cooperation with integrin alpha2. , 2009, Biochemical and biophysical research communications.

[27]  I. Kovalszky,et al.  An Immunohistochemical Study of Colon Adenomas and Carcinomas: E-cadherin, Syndecan-1, Ets-1 , 2009, Pathology & Oncology Research.

[28]  B. Molnár,et al.  Potential Biomarkers of Colorectal Adenoma–Dysplasia–Carcinoma Progression: mRNA Expression Profiling and In Situ Protein Detection on TMAs Reveal 15 Sequentially Upregulated and 2 Downregulated Genes , 2008, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[29]  K. Mimori,et al.  CD133+CD44+ Population Efficiently Enriches Colon Cancer Initiating Cells , 2008, Annals of Surgical Oncology.

[30]  Wancai Yang,et al.  Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. , 2008, Carcinogenesis.

[31]  A. Tsatsakis,et al.  Heparin—A unique stimulator of human colon cancer cells' growth , 2008, IUBMB life.

[32]  E. Grigorieva,et al.  Expression of different proteoglycans in human breast tumors , 2007, Biochemistry (Moscow).

[33]  J. Isola,et al.  Epithelial Syndecan-1 Expression Is Associated with Stage and Grade in Colorectal Cancer , 2005, Oncology.

[34]  S. Mukaratirwa,et al.  Mutual paracrine effects of colorectal tumour cells and stromal cells: modulation of tumour and stromal cell differentiation and extracellular matrix component production in culture , 2005, International journal of experimental pathology.

[35]  R. Iozzo,et al.  Altered proteoglycan gene expression and the tumor stroma , 1993, Experientia.

[36]  A. Theocharis,et al.  Matrix proteoglycans are markedly affected in advanced laryngeal squamous cell carcinoma. , 2004, Biochimica et biophysica acta.

[37]  S. Bressler,et al.  The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. , 2004, Critical reviews in eukaryotic gene expression.

[38]  A. Hjerpe,et al.  Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium , 2003, The Journal of pathology.

[39]  A. Theocharis.  Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin. , 2002, Biochimica et biophysica acta.

[40]  James Melrose,et al.  Electrophoretic, biosensor, and bioactivity analyses of perlecans of different cellular origins , 2001, Proteomics.

[41]  S. Tumova,et al.  Epidermal transformation leads to increased perlecan synthesis with heparin-binding-growth-factor affinity. , 2001, The Biochemical journal.

[42]  T. Yamamoto,et al.  Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. , 2001, Biochemical and biophysical research communications.

[43]  R. Kokenyesi.  Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix , 2001, Journal of cellular biochemistry.

[44]  M. Nugent,et al.  Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. , 1998, The Journal of clinical investigation.

[45]  A. Bassols,et al.  Changes in glycosaminoglycan structure and composition of the main heparan sulphate proteoglycan from human colon carcinoma cells (perlecan) during cell differentiation. , 1998, European journal of biochemistry.

[46]  K. Nackaerts,et al.  Heparan sulfate proteoglycan expression in human lung‐cancer cells , 1997, International journal of cancer.

[47]  H. Larjava,et al.  Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture. , 1991, The Journal of biological chemistry.

[48]  R. Ádány,et al.  Altered methylation of versican proteoglycan gene in human colon carcinoma. , 1990, Biochemical and biophysical research communications.

[49]  R. Ádány,et al.  Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. , 1990, The Journal of biological chemistry.